Global Genotoxicity Testing and Mutagenicity Testing Services Market Report to 2035: Players Include Aurigene Pharmaceutical Services, Sai Life Sciences, LSIM Safety Institute and GLR Laboratories - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Genotoxicity Testing and Mutagenicity Testing Services Market: Distribution by Type of Assay, Assay / Test Offered, End User Industry and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study of the current market landscape and future potential of genotoxicity and mutagenicity testing services.
- Charles River Laboratories
- Aurigene Pharmaceutical Services
- Sai Life Sciences
- LSIM Safety Institute
- GLR Laboratories
The report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. It also answers many key questions related to this domain; some of these have been mentioned below.
Genotoxicity refers to the property of hazardous (physical, chemical and biological) agents to cause damage to genetic information present within a cell. It is worth mentioning that this damage can lead to formation of mutations, activation of mistimed event and direct DNA damage.
Further, researchers have been able to link the mutations caused by genetic toxicology to various disease indications, including several oncological and genetic disorders. In addition, it is believed that the changes introduced in the genetic material can be passed down to future cell generations. Similarly, mutagenicity refers to the introduction of perpetual transmissible changes in the genomic structure of organisms, enabling mutations in cells.
Therefore, testing of genotoxicity / mutagenicity is an essential component of the safety assessment of products, with the objective of preventing certain particles from negatively impacting the human health. At present, genotoxicity tests are frequently employed across several industries, such as healthcare, chemical, cosmetic, food and agriculture, in order to determine whether a particular compound induces damage.
However, since there is no particular test available for identifying all relevant genotoxic endpoints, a series of in vivo and in vitro genotoxicity testing techniques are employed to assess the safety of healthcare compounds. For instance, short-term tests (STTs), such as Ames test and micronucleus assay, determine the genotoxic potential of hazardous chemicals.
These tests usually assess the safety of environmental chemicals and consumer products, as well as investigate the mode of action of suspected carcinogens.
Additionally, with the rapid development of next generation sequencing technology, several new methods for genotoxicity testing have been introduced that can enable players to directly analyze the genetic materials.
However, owing to the lack of required chemistry capabilities and limited in-house expertise, the stakeholders have started relying on testing service providers for assessing the safety of their compounds. Overall, the growing demand for testing of healthcare products and the stringent safety requirements established by several regulatory bodies across the globe, has created lucrative opportunities for genotoxicity / mutagenicity testing service providers.
Frequently Asked Questions
Question 1: What is the growth rate of genotoxicity and mutagenicity testing services market?
Answer: The global market for genotoxicity and mutagenicity testing service market is expected to grow at a growth rate of 5% - 9% from 2023 to 2035.
Question 2: Which region will lead the genotoxicity and mutagenicity testing service market?
Answer: North America is anticipated to drive the market revenues, by 2035. In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace, in the long term.
Question 3: Which segment, in terms of type of assay offered, dominates the genotoxicity and mutagenicity testing service market?
Answer: Currently, in vivo assays dominate the genotoxicity and mutagenicity testing service market. However, in the foreseen future, in vitro assays are expected to influence the market with a higher share in 2035.
Question 4: Which segment, in terms of type of end users, accounts for the largest share in the genotoxicity and mutagenicity testing service market?
Answer: Chemical industries are anticipated to capture over 65% of the market share by 2035. In addition, the market for healthcare industries is likely to grow at a relatively faster pace, in the long term.
Question 5: What type of partnership models are most commonly being adopted by stakeholders engaged in this domain?
Answer: Acquisitions emerged as the most popular type of partnership model adopted by players engaged in offering genotoxicity and mutagenicity testing services. This is followed by platform licensing agreements and service alliances.
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. MARKET LANDSCAPE
5. BENCHMARKING ANALYSIS
6. COMPANY PROFILES
7. PUBLICATION BENCHMARKING ANALYSIS
8. GRANTS ANALYSIS
9. PARTNERSHIPS AND COLLABORATIONS
10. PATENT ANALYSIS
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/ylndsq
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900